Have a personal or library account? Click to login
IL-17B Inhibits Hepatocellular Carcinoma Cell Proliferation Cover

References

  1. Adunyah SE, Akomeah RKN, Arthur FS et al. (2021) IL-17 biological effects and signaling mechanisms in human leukemia U937 cells. In: Behzadi P (ed) Interleukins – The immune and non-immune systems’ related cytokines. IntechOpen. https://doi.org/10.5772/intechopen.96422
  2. Al-Samadi A, Moossavi S, Salem A et al. (2016) Distinctive expression pattern of interleukin-17 cytokine family members in colorectal cancer. Tumour Biol 37:1609–1615. https://doi.org/10.1007/s13277-015-3941-x
  3. Arvanitakis K, Mitroulis I, Germanidis G (2021) Tumor-associated neutrophils in hepatocellular carcinoma pathogenesis, prognosis, and therapy. Cancers (Basel) 13:2899. https://doi.org/10.3390/cancers13122899
  4. Benatar T, Cao MY, Lee Y et al. (2010) IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol Immunother 59:805–817. https://doi.org/10.1007/s00262-009-0802-8
  5. Bie Q, Jin C, Zhang B et al. (2017a) IL-17B: A new area of study in the IL-17 family. Mol Immunol 90:50–56. https://doi.org/10.1016/j.molimm.2017.07.004
  6. Bie Q, Sun C, Gong A et al. (2016) Non-tumor tissue derived interleukin-17B activates IL-17RB/AKT/beta-catenin pathway to enhance the stemness of gastric cancer. Sci Rep 6:25447. https://doi.org/10.1038/srep25447
  7. Bie Q, Zhang B, Sun C et al. (2017b) IL-17B activated mesenchymal stem cells enhance proliferation and migration of gastric cancer cells. Oncotarget 8:18914–18923. https://doi.org/10.18632/oncotarget.14835
  8. Cai L, Yin JP, Starovasnik MA et al. (2001) Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 16:10–21. https://doi.org/10.1006/cyto.2001.0939
  9. Chen X, Zhang L, He L et al. (2023) Potassium channels as novel molecular targets in hepatocellular carcinoma (review). Oncol Rep 50:185. https://doi.org/10.3892/or.2023.8622
  10. Crowley LC, Christensen ME, Waterhouse NJ (2016) Measuring survival of adherent cells with the colony-forming assay. Cold Spring Harb Protoc 2016 (8). https://doi.org/10.1101/pdb.prot087171
  11. Czauderna C, Castven D, Mahn FL et al. (2019) Context-dependent role of NF-kappaB signaling in primary liver cancer-from tumor development to therapeutic implications. Cancers 11:1053. https://doi.org/10.3390/cancers11081053
  12. Furuta S, Jeng YM, Zhou L et al. (2011) IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med 3:78ra31. https://doi.org/10.1126/scitranslmed.3001374
  13. Ge SX, Jung D, Yao R (2020) ShinyGO: A graphical gene-set enrichment tool for animals and plants. Bioinformatics 36:2628–2629. https://doi.org/10.1093/bioinformatics/btz931
  14. Guzmán C, Bagga M, Kaur A et al. (2014) ColonyArea: An ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS One 9:e92444. https://doi.org/10.1371/journal.pone.0092444
  15. Huang CK, Yang CY, Jeng YM et al. (2014) Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-kappaB-mediated antiapoptotic pathway. Oncogene 33:2968–2977. https://doi.org/10.1038/onc.2013.268
  16. Ichinohe N, Ishii M, Tanimizu N et al. (2017) Transplantation of Thy1(+) cells accelerates liver regeneration by enhancing the growth of small hepatocyte-like progenitor cells via IL17RB signaling. Stem Cells 35:920–931. https://doi.org/10.1002/stem.2548
  17. Jacobs MD, Harrison SC (1998) Structure of an IkappaBalpha/NF-kappaB complex. Cell 95:749–758. https://doi.org/10.1016/s0092-8674(00)81698-0
  18. Jaillon S, Galdiero MR, Del Prete D et al. (2013) Neutrophils in innate and adaptive immunity. Semin Immunopathol 35:377–394. https://doi.org/10.1007/s00281-013-0374-8
  19. Jiang Z, Chen J, Du X et al. (2017) IL-25 blockade inhibits metastasis in breast cancer. Protein Cell 8:191–201. https://doi.org/10.1007/s13238-016-0345-7
  20. Karaś K, Karwaciak I, Chałaśkiewicz K et al. (2023) Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519. Biomed Pharmacother 164:115002. https://doi.org/10.1016/j.biopha.2023.115002
  21. Karwaciak I, Sałkowska A, Karaś K et al. (2019) SIRT2 contributes to the resistance of melanoma cells to the multikinase inhibitor dasatinib. Cancers (Basel) 11:673. https://doi.org/10.3390/cancers11050673
  22. Laprevotte E, Cochaud S, du Manoir S et al. (2017) The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway. Oncotarget 8:113360–113372. https://doi.org/10.18632/oncotarget.23008
  23. Lee J, Ho WH, Maruoka M et al. (2001) IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem 276:1660–1664. https://doi.org/10.1074/jbc.M008289200
  24. Lemancewicz D, Bolkun L, Jablonska E et al. (2012) The role of interleukin-17A and interleukin-17E in multiple myeloma patients. Med Sci Monit 18:BR54–59. https://doi.org/10.12659/msm.882204
  25. Liu Y, Fuchs J, Li C et al. (2010) IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle 9:3423–3427. https://doi.org/10.4161/cc.9.17.12946
  26. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https://doi.org/10.1186/s13059-014-0550-8
  27. Luo Y, Yang Z, Su L et al. (2016) Non-CSCs nourish CSCs through interleukin-17E-mediated activation of NF-kappaB and JAK/STAT3 signaling in human hepatocellular carcinoma. Cancer Lett 375:390–399. https://doi.org/10.1016/j.canlet.2016.03.012
  28. Mathes E, O’Dea EL, Hoffmann A et al. (2008) NF-kappaB dictates the degradation pathway of IkappaBalpha. EMBO J 27: 1357–1367. https://doi.org/10.1038/emboj.2008.73
  29. Moseley TA, Haudenschild DR, Rose L et al. (2003) Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14: 155–174. https://doi.org/10.1016/s1359-6101(03)00002-9
  30. Ren L, Xu Y, Liu C et al. (2017) IL-17RB enhances thyroid cancer cell invasion and metastasis via ERK1/2 pathway-mediated MMP-9 expression. Mol Immunol 90:126–135. https://doi.org/10.1016/j.molimm.2017.06.034
  31. Reynolds JM, Lee YH, Shi Y et al. (2015) Interleukin-17B antagonizes interleukin-25-mediated mucosal inflammation. Immunity 42:692–703. https://doi.org/10.1016/j.immuni.2015.03.008
  32. Sanders AJ, Guo X, Mason MD et al. (2010) IL-17B can impact on endothelial cellular traits linked to tumour angiogenesis. J Oncol 2010:817375. https://doi.org/10.1155/2010/817375
  33. Shi Y, Ullrich SJ, Zhang J et al. (2000) A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 275:19167–19176. https://doi.org/10.1074/jbc.M910228199
  34. Sun VC, Sarna L (2008) Symptom management in hepatocellular carcinoma. Clin J Oncol Nurs 12:759–766. https://doi.org/10.1188/08.CJON.759-766
  35. Tan K, Stupack DG, Wilkinson MF (2022) Nonsense-mediated RNA decay: An emerging modulator of malignancy. Nat Rev Cancer 22:437–451. https://doi.org/10.1038/s41568-022-00481-2
  36. Tan Y, Lin XT, Luo YD et al. (2020) Reduced IkappaBalpha promotes hepatocellular carcinoma cell proliferation and migration via regulation of NF-kappaB/Erbin axis. Oncol Lett 20:216. https://doi.org/10.3892/ol.2020.12079
  37. Tian LY, Smit DJ, Jucker M (2023) The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism. Int J Mol Sci 24:2652. https://doi.org/10.3390/ijms24032652
  38. Vandesompele J, De Preter K, Pattyn F et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034. https://doi.org/10.1186/gb-2002-3-7-research0034
  39. Wang H, Liu Y, Yang L et al. (2025) Differential roles of IL-17B and IL-17RB in colorectal cancer: Correlation with immune infiltration and prognosis. Pathol Res Pract 268:155847. https://doi.org/10.1016/j.prp.2025.155847
  40. Wu HH, Hwang-Verslues WW, Lee WH et al. (2015) Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. J Exp Med 212:333–349. https://doi.org/10.1084/jem.20141702
  41. Xu J, Lin H, Wu G et al. (2021) IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front Oncol 11:760971. https://doi.org/10.3389/fonc.2021.760971
  42. Yang YF, Lee YC, Lo S et al. (2018) A positive feedback loop of IL-17B-IL-17RB activates ERK/beta-catenin to promote lung cancer metastasis. Cancer Lett 422:44–55. https://doi.org/10.1016/j.canlet.2018.02.037
  43. Zenobia C, Hajishengallis G (2015) Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol 2000 69: 142–159. https://doi.org/10.1111/prd.12083
Language: English
Published on: Jun 17, 2025
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2025 Joanna Pastwińska, Iwona Karwaciak, Kaja Karaś, Daria Grabarczyk, Anna Sałkowska, Marcin Ratajewski, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.